CAR-T Meeting 2022 | Challenges of CAR-T therapy in clinical practice: clinical trials vs real-world data
Stephan Mielke, MD, PhD, Karolinska Institute, Solna, Sweden, comments on some of the obstacles to implementing chimeric antigen receptor T-cell (CAR-T) therapy in clinical practice. Prof. Mielke explains that the application of clinical trial results to clinical practice is not straightforward as trials have restrictive enrollment criteria and label indications are limited. Real-world experiences in clinical practice will enable us to gain a better understanding of the best strategies to treat and follow-up patients receiving CAR-T therapies, and to manage side effects appropriately. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Celgene/BMS, Novartis, DNA Prime SA: Speakers bureau (via institution)
Gilead/KITE: Other: Travel support, Expert panel (via institution)
Miltenyi, Immunicum: Other: Data safety monitoring board (via institution)
